Key result
Atrial cardiopathy marker PTFV1 > 5000 μV·ms linked to ~70% higher 1-year mortality after ischemic stroke.
Why the study?
Whether atrial cardiopathy is associated with stroke prognosis remains unclear.
Are atrial cardiopathy markers associated with an increased risk of death and ischemic stroke recurrence in patients with acute ischemic stroke?
Cohort
Yes
Are atrial cardiopathy markers associated with an increased risk of death and ischemic stroke recurrence in patients with acute ischemic stroke?
Atrial cardiopathy markers, specifically PTFV1 > 5000 μV·ms and advanced interatrial block, are independent predictors of 1-year mortality and stroke recurrence in patients with acute ischemic stroke, even in the absence of diagnosed atrial fibrillation.
Answers are grounded in this paper and cite their sources.
PTFV1 >5000 μV·ms associated with higher post-stroke mortality; leaves open whether markers should guide monitoring or trials beyond AF.
Introduction: Whether atrial cardiopathy is associated with stroke prognosis remains unclear. We evaluated the association between atrial cardiopathy markers and outcomes in patients with ischemic stroke using a nationwide prospective registry. Patients and methods: Based on the Third China National Stroke Registry, we evaluated different atrial cardiopathy markers including increased P-wave terminal force in V1 (PTFV1), advanced interatrial block (aIAB), prolonged P-wave duration, prolonged P-wave dispersion, paroxysmal supraventricular tachycardia, premature atrial contractions, prolonged PR interval, and severe left atrial enlargement in ischemic stroke patients. The outcomes were death and ischemic stroke recurrence at 1 year. The association between atrial cardiopathy markers and outcomes was analyzed using Cox regression models. Results: At 1-year follow-up, 486 (3.4%) patients had died and 1317 (9.3%) patients had experienced ischemic stroke recurrence. After adjustment for clinical risk factors including atrial fibrillation, PTFV1 > 5000 μV·ms (adjusted hazard ratio [HR] 1.70, 95% confidence interval [CI]: 1.18–2.45, p = 0.004) and aIAB (adjusted HR 1.47, 95% CI: 1.14–1.91, p = 0.003) were significantly associated with mortality. PTFV1 > 5000 μV·ms was significantly associated with ischemic stroke recurrence (adjusted HR 1.54, 95% CI: 1.22–1.96, p = 0.0004). This association was observed although we excluded patients diagnosed with atrial fibrillation. Discussion and Conclusion: Atrial cardiopathy markers, especially PTFV1 and aIAB, are significantly associated with a higher risk of poor prognosis in patients with ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2022) conducted a cohort in acute ischemic stroke. Atrial cardiopathy markers (PTFV1, aIAB) was evaluated on Death and ischemic stroke recurrence at 1 year (HR 1.70, 95% CI 1.18-2.45, p=0.004). Atrial cardiopathy markers, specifically PTFV1 > 5000 μV·ms, were significantly associated with increased 1-year mortality (HR 1.70; 95% CI 1.18-2.45; p=0.004) in patients with ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: